


PF-06869206

## Chemical Properties

CAS No. : 2227425-05-8  
 Formula: C<sub>15</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>  
 Molecular Weight: 374.75  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



## Biological Description

|                            |   |
|----------------------------|---|
| Description                | PF-06869206 is an oral selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1, IC <sub>50</sub> : 380 nM).   |
| Targets(IC <sub>50</sub> ) | Sodium-dependent phosphate transporter, Sodium Channel  |
| In vitro                   | PF-06869206 (380 nM) shows NaPi2a inhibition potency. PF-06869206 is profiled for potency in the rodent NaPi2a and NaPi2c cell lines. PF-06869206 shows comparable submicromolar activity for the human, rat, and mouse NaPi2a isoforms (IC <sub>50</sub> s: 0.4 μM/0.54 μM for rat/mouse NaPi2a).  |
| In vivo                    | In rodent PK, PF-06869206 show moderate clearance in both rat and mouse. Oral bioavailability at 5 mg/kg is good in rat and moderate in mouse. At higher oral doses of 50 mg/kg, supraproportional increases in exposure are observed in both species, suggestive of saturation of clearance. PF-06869206 has moderate terminal elimination half-life (t <sub>1/2</sub> =1.35 h, and 0.75 h for Wistar-Han rats (10 mg/kg, iv), and C57BL6 mice (1 mg/kg, iv)). |
| Animal Research            | Male Wistar-Han rats are treated with PF-06869206 (1 mg/kg, 5 mg/kg, and 50 mg/kg; 2 mL/kg for iv or 10 mL/kg for po). C57BL6 mice are treated with PF-06869206 (1 mg/kg, 5 mg/kg, and 50 mg/kg; 2 mL/kg for iv or 10 mL/kg for po).  |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | DMSO: 120 mg/mL (320.21 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.67 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 2.6684 mL | 13.3422 mL | 26.6845 mL |
| 5 mM  | 0.5337 mL | 2.6684 mL  | 5.3369 mL  |
| 10 mM | 0.2668 mL | 1.3342 mL  | 2.6684 mL  |
| 50 mM | 0.0534 mL | 0.2668 mL  | 0.5337 mL  |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Filipski KJ, et al. Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1). ACS Med Chem Lett. 2018 Apr 12;9(5):440-445.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481